Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
AKTX 
Akari Therapeutics PLC (AKTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: AKTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7
1 Year Target Price $7
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 24.9% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 37.30M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 1 | Beta 0.25 | 52 Weeks Range 0.85 - 4.40 | Updated Date 06/30/2025 |
52 Weeks Range 0.85 - 4.40 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -32.99% | Return on Equity (TTM) -197.11% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 36559630 | Price to Sales(TTM) - |
Enterprise Value 36559630 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.06 | Shares Outstanding 32176400 | Shares Floating 10364652304 |
Shares Outstanding 32176400 | Shares Floating 10364652304 | ||
Percent Insiders 34.7 | Percent Institutions 0.98 |
Analyst Ratings
Rating 1 | Target Price 7 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Akari Therapeutics PLC
Company Overview
History and Background
Akari Therapeutics PLC is a late-stage biopharmaceutical company focused on developing innovative therapeutics to treat orphan autoimmune and inflammatory diseases where significant unmet needs exist. Founded to advance therapies for conditions driven by dysregulation of complement and leukotriene pathways.
Core Business Areas
- Rare Disease Therapeutics: Focuses on developing treatments for rare autoimmune and inflammatory diseases, particularly those related to complement system dysregulation.
Leadership and Structure
Details about leadership are not readily available in public sources. Publicly traded company with the usual structure for biopharmaceutical firm.
Top Products and Market Share
Key Offerings
- Nomacopan: Nomacopan (coversin) is Akari's lead drug candidate, a second-generation complement inhibitor that targets C5. It is being developed for several indications, including bullous pemphigoid (BP). Market share data is unavailable as it is not yet approved, but competitors in BP include corticosteroids, rituximab (RTX), and tetracycline.
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on rare and orphan diseases is experiencing significant growth. High unmet medical needs and regulatory incentives drive innovation and investment.
Positioning
Akari is positioned as a company focusing on targeted therapies for rare complement-mediated diseases, a niche market with potential for high value.
Total Addressable Market (TAM)
TAM varies depending on the specific indication. For bullous pemphigoid, the market is substantial given the incidence and lack of optimal treatments. Precise TAM figures require detailed market analysis, but coversin is well positioned if approved.
Upturn SWOT Analysis
Strengths
- Novel drug candidate (Nomacopan)
- Focus on orphan diseases with high unmet needs
- Targeting complement inhibition, a validated therapeutic pathway
Weaknesses
- Reliance on a single drug candidate
- Limited financial resources
- High risk of clinical trial failure
Opportunities
- Potential for accelerated approval pathways for orphan drugs
- Expansion into new indications for Nomacopan
- Partnerships with larger pharmaceutical companies
Threats
- Clinical trial failures
- Competition from existing and emerging therapies
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- ALXN
- VRCA
- KALV
Competitive Landscape
Akari's competitive advantage lies in its novel complement inhibitor, Nomacopan. However, it faces competition from established players with approved therapies and greater financial resources. Vertex, Alexion, and Kalvista are significantly larger with multiple marketed products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth depends on the clinical trial results. Success of trials in previous periods were minimal, which reduced company value.
Future Projections: Future growth is highly dependent on the success of Nomacopan in ongoing clinical trials. Analyst projections are not readily available without specific financial data sources.
Recent Initiatives: Focusing on completing clinical trials for Nomacopan in bullous pemphigoid and other indications.
Summary
Akari Therapeutics is a clinical-stage biopharmaceutical company focusing on rare diseases and is considered very weak as it is not revenue generating. The key driver for future success is the clinical success and eventual approval of Nomacopan. The company faces challenges from larger competitors and the inherent risks of drug development. It needs funding and success to stay afloat.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share percentages are estimates and may not reflect precise figures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Akari Therapeutics PLC
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2015-09-21 | CEO, President & Director Mr. Abizer Gaslightwala | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.akaritx.com |
Full time employees 8 | Website https://www.akaritx.com | ||
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.